Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 190 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Cancer “Decoys” Planted Underneath The Skin Lure In Cancer Cells And... November 4, 2019 Being Diagnosed With a Childhood Cancer As an Adult Led Me... May 18, 2023 Doctor Wipes Away The Debt Of 200 Cancer Patients January 6, 2021 The digital shift: How are remote GP appointments affecting cancer patients? December 17, 2021 Load more HOT NEWS Geriatric Assessment Intervention Reduces Patient-Reported Symptomatic Toxicities in Older Patients with... Oxaliplatin-Based Adjuvant Chemotherapy Shows Good Tolerance and Similar Time To Recurrence... Routes to a healthier shopping journey – how your supermarket environment... 6-Yr-Old With Cerebral Palsy Receives Dream Gift After Learning To Walk.
